基本情報
研究キーワード
4研究分野
1委員歴
5-
2012年 - 2014年
-
2014年
-
2014年
-
2014年
-
2012年
受賞
7-
2010年3月
-
2009年5月
-
2006年11月
-
2002年7月
論文
969-
Journal of the American Heart Association 14(2) e034627 2025年1月21日BACKGROUND: The effect of worsening renal function and baseline chronic kidney disease (CKD) on outcomes in patients with chronic coronary syndrome in the setting of optimal medical therapy remains unknown. METHODS AND RESULTS: The REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) study is a prospective, multicenter, randomized trial of high-dose (pitavastatin 4 mg/day) or low-dose (pitavastatin 1 mg/day) statin therapy in 12 118 patients with chronic coronary syndrome. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or unstable angina requiring hospitalization (major adverse cardiac and cerebral events [MACCE]). CKD was defined as an estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2. WRF was defined as a decrease in eGFR ≥20% in the initial year; borderline renal function was an annual decrease of 0%<eGFR<20%, and stable renal function was no decrease. Of 12 118 patients, 4340 had baseline CKD and 7778 did not. The rate of MACCE at 5 years was significantly lower in those without (5.5%) versus with CKD (9.5%) (P<0.0001). After excluding 1247 patients who had MACCE, were censored, or missing eGFR within 1 year, 10 871 patients were included. Of these, 3885 were baseline CKD and the remaining 6986 did not have baseline CKD. Of the 10 871 patients, 577 patients had WRF, 6014 patients showed borderline renal function, and the remaining 4280 patients maintained stable renal function. In patients with CKD, WRF was an independent predictor for MACCE at 4 years as compared with stable renal function (hazard ratio [HR]: 1.67; [95% CI, 1.03-2.73; P=0.039]). In patients without CKD, borderline renal function was a significant predictor for MACCE at 4 years compared with stable renal function (HR: 1.40 [95% CI, 1.03-1.91; P=0.032]). CONCLUSIONS: Baseline CKD was an independent predictor for MACCE in patients with CCS. WRF was a significant predictor for MACCE in patients with CKD. Because borderline renal function was an independent predictor for MACCE even in patients without CKD, mild-to-moderate annual declines of eGFR should be carefully monitored (NCT01042730). REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01042730.
-
International Journal of Molecular Sciences 26(2) 556-556 2025年1月10日 査読有り
-
IJC Heart & Vasculature 54 101507-101507 2024年10月
-
Hypertension research : official journal of the Japanese Society of Hypertension 2024年9月19日The Japanese Society of Hypertension have established a blood pressure (BP) target of 130/80 mmHg for patients with coronary artery disease (CAD). We evaluated the data of 8793 CAD patients in the Clinical Deep Data Accumulation System database who underwent cardiac catheterization at six university hospitals and the National Cerebral and Cardiovascular Center (average age 70 ± 11 years, 78% male, 43% with acute coronary syndrome [ACS]). Patients were divided into two groups based on whether or not they achieved the guideline-recommended BP of <130/80 mmHg. We analyzed the relationship between BP classification and major adverse cardiac and cerebral event (MACCE) separately in two groups: those with ACS and those with chronic coronary syndrome (CCS). During an average follow-up period of 33 months, 710 MACCEs occurred. A BP below 130/80 mmHg was associated with fewer MACCEs in both the overall (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.70-1.00, p = 0.048) and the ACS group (HR 0.67, 95%CI 0.51-0.88, p = 0.003). In particular, stroke events were also lower among those with a BP below 130/80 mmHg in both the overall (HR 0.69, 95%CI 0.53-0.90, p = 0.006) and ACS groups (HR 0.44, 95%CI 0.30-0.67, p < 0.001). In conclusion, the achievement of BP guidelines was associated with improved outcomes in CAD patients, particularly in reducing stroke risk among those with ACS.
MISC
1923-
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 249(3) 865-871 1998年8月
-
Journal of biochemistry 124(2) 389-95 1998年8月 査読有り
-
American heart journal 136(2) 362-3 1998年8月 査読有り
-
Cardiovascular drugs and therapy 12(3) 251-60 1998年7月 査読有り
-
Research communications in molecular pathology and pharmacology 101(1) 25-34 1998年7月 査読有り
-
NEPHRON 79(3) 317-321 1998年7月
-
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 248(2) 324-329 1998年7月
-
Circulation research 82(12) 1238-42 1998年6月29日 査読有り
-
JOURNAL OF HYPERTENSION 16 S181-S181 1998年6月
-
JOURNAL OF HYPERTENSION 16 S133-S133 1998年6月
-
JOURNAL OF HYPERTENSION 16 S85-S85 1998年6月
-
JOURNAL OF HYPERTENSION 16 S134-S134 1998年6月
-
JOURNAL OF HYPERTENSION 16 S125-S125 1998年6月
-
PATHOLOGY INTERNATIONAL 48(6) 433-439 1998年6月
-
Research communications in molecular pathology and pharmacology 100(3) 327-38 1998年6月 査読有り
-
INTERNAL MEDICINE 37(6) 528-533 1998年6月
-
American journal of hypertension 11(6 Pt 1) 697-707 1998年6月 査読有り
-
GENE THERAPY 5(6) 761-769 1998年6月
-
DIABETES 47 A201-A201 1998年5月
-
JOURNAL OF NUCLEAR MEDICINE 39(5) 153P-153P 1998年5月
-
DIABETES 47 A393-A393 1998年5月
-
JOURNAL OF NUCLEAR MEDICINE 39(5) 152P-152P 1998年5月
-
JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION 62(5) 389-391 1998年5月
-
Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie 197(6) 319-28 1998年4月 査読有り
-
Human genetics 102(4) 435-9 1998年4月 査読有り
-
Japanese circulation journal 61 816-816 1998年3月20日
-
Circulation research 82(4) 430-7 1998年3月9日 査読有り
-
Japanese circulation journal 62(3) 160-6 1998年3月 査読有り
-
FEBS LETTERS 424(1-2) 6-10 1998年3月
-
Japanese circulation journal 62 244-244 1998年2月28日
-
Japanese circulation journal 62 235-235 1998年2月28日
-
Japanese circulation journal 62 534-534 1998年2月28日
-
Japanese circulation journal 62 517-517 1998年2月28日
-
Japanese circulation journal 62 315-315 1998年2月28日
書籍等出版物
21-
Springer 2009年 (ISBN: 9784431877745)
-
Signal Transduction and Cardiac Hypertrophy (Naranjan S. Dhalla, Larry Hryshko, Elissavet Kardami, Pawan K. Singal, KLUWER ACADEMIC PUBLISHERS) 2003年
-
Signal Transduction and Cardiac Hypertrophy (Naranjan S. Dhalla, Larry Hryshko, Elissavet Kardami, Pawan K. Singal, KLUWER ACADEMIC PUBLISHERS) 2003年
-
Rapid Cycle Real-Time PCR : methods and applications 2001年
-
in"The Hypertrophied Heart" 2000年
共同研究・競争的資金等の研究課題
91-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 2020年7月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2018年6月 - 2023年3月